CEO David Cordani is not convinced of the benefits of GLP-1s for weight-loss patients and said the US is the only country ...

Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, ...

Eli Lilly and Novo Nordisk are in a global battle for dominance in the weight loss space. BioSpace takes a look at the ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

With GLP-1 drugs like Ozempic all the rage, ChipMonk Baking has created a cookie it says works a bit the same way.

GLP-1s are driving traditional drug spending in the U.S. to unprecedented levels, which now outpaces specialty drug spending ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...

Spending growth for simple medications used to treat common health problems is outstripping spending growth for pricey medications used to treat complex and chronic conditions, according to a new ...

Spending on GLP-1 drugs continues to rise, after outpacing trends among specialty drugs for the first time in 2023, according ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

The newest generation of GLP-1 drugs has delivered life-changing benefits to patients managing diabetes, obesity, heart ...

The U.S. equity market has had a solid run in the past two years, buoyed by a steadily improving macroeconomic environment ...